What is the drug profile and indications of filgotinib?

Filgotinib(Filgotinib) is an oral small molecule selective Janus kinase 1 (JAK1) inhibitor that belongs to the targeted immunomodulatory drug class. Its main mechanism of action is to selectively inhibit JAK1 and block pro-inflammatory cytokine signaling, thereby reducing inflammatory responses and improving immune system imbalance. This targeting effect enables filgotinib to show high efficacy and safety in the treatment of autoimmune diseases. Compared with traditional broad-spectrum immunosuppressants, it has less interference with other physiological functions while regulating the inflammatory response, thereby reducing the risk of serious infection and systemic toxic side effects.

Clinically, filgotinib has been approved for the treatment of adults with active moderate to severe rheumatoid arthritis (RA). It is suitable for patients who have not achieved satisfactory response after treatment with one or more disease-modifying antirheumatic drugs (DMARDs), especially when traditional antirheumatic drugs or biologics have not responded well or are not tolerated. Figotinib can be an effective alternative. At the same time, the drug is also used to treat moderately to severely active ulcerative colitis (UC), providing a new oral treatment option for this refractory inflammatory bowel disease. By inhibiting the JAK1 pathway, filgotinib can reduce intestinal mucosal inflammation, relieve symptoms and improve quality of life. It is an important representative of current oral small molecule anti-inflammatory drugs.

In terms of drug metabolism, filgotinib is mainly metabolized through the liverCYP3A4 pathway, and there is also a small amount of renal clearance. It has high oral bioavailability and moderate half-life, allowing for a convenient once- or twice-daily administration regimen, meeting the needs of long-term chronic disease management. Clinical studies have shown that it can effectively improve joint pain, morning stiffness and mobility in patients with arthritis. It can also improve symptoms such as diarrhea, blood in the stool and abdominal pain in patients with ulcerative colitis, significantly improving the patient's quality of life.

Reference materials:https://go.drugbank.com/drugs/DB14845